Dare Bioscience, Inc. current report, 16 April 2026

Business Context and Reporting Period

Daré Bioscience, Inc. (Nasdaq: DARE) filed a Form 8-K Current Report dated April 16, 2026. The filing addresses a corporate governance matter regarding the reclassification of a director to rebalance the board's class structure.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board composition changes and contains no financial performance data.

Material Changes

The material change reported is the voluntary resignation and simultaneous reappointment of Gregory W. Matz. He resigned from his position as a Class II director (term expiring 2028) and was reappointed as a Class III director (term expiring 2026). This action was taken solely to rebalance the three classes of the six-member board of directors. His service is deemed uninterrupted, and there were no changes to his committee assignments.

Guidance, Outlook, and Risks

The filing contains no management commentary on financial guidance, outlook, risks, contingencies, or unusual items. The document is limited to the procedural details of the director's reclassification.

Investor Verification Checklist

  • Verify the updated board composition and class terms for the upcoming 2026 annual meeting of stockholders.
  • Confirm that Gregory W. Matz and Sabrina Martucci Johnson are the designated Class III directors standing for re-election.
  • Review the company's proxy statement for the 2026 annual meeting for further details on director elections.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.